Physician profile
John E Stanback
NPI 1629034764
$4,789.87
in general payments reported to CMS, 2019-2025
26 companies · $56.44 in 2025
The $56.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $980 · 2020: $745 · 2021: $898 · 2022: $1,122 · 2023: $732 · 2024: $255 · 2025: $56.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $930.62 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $734.56 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $619.21 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $293.98 | 2021-2025 | |
| Abbvie INC. | $292.28 | 2021-2024 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $279.49 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.56 | 2019-2023 | Jardiance, Synjardy |
| Lilly USA, LLC | $271.04 | 2019-2023 | Jardiance, Emgality |
| Amgen INC. | $187.11 | 2019-2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $126.07 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $108.83 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $106.57 | 2020-2022 | |
| Esperion Therapeutics, INC. | $95.46 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.40 | 2020-2021 | |
| Glaxosmithkline, LLC. | $83.26 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $71.43 | 2024 | Voquezna |
| Pfizer INC. | $51.39 | 2019-2022 | |
| Allergan, INC. | $36.79 | 2019-2020 | |
| Ucb, INC. | $26.14 | 2019 | |
| Boston Scientific Corporation | $21.65 | 2022 | |
| Astellas Pharma US INC | $17.65 | 2020 | |
| Abbott Laboratories | $16.31 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $15.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.49 | 2023 | Quviviq |
| Linus Health, INC. | $14.46 | 2023 | |
| Tactile Systems Technology INC | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stanback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.